Abiopharma

🔍 Yang Watkin Phoebe L. (Director)

Company: GE HealthCare Technologies Inc. (GEHC)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 3,586 shares of Common Stock, par value $0.01 per share (Direct)
  Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 12,702.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,000 shares of Common Stock, par value $0.01 per share at $63.0063 per share (Direct)
  Date: 2026-05-08 | Code: P | equity_swap_involved: 0 | shares_owned_after: 13,702.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Award of restricted stock units with respect to GE HealthCare Technologies Inc. ("GE HealthCare") common stock, of which 100% will vest on the earlier of: (i) the date of GE HealthCare's next annual meeting of stockholders and (ii) May 7, 2027. Settlement of vested restricted stock units may be deferred by the director, in which case, settlement will occur pursuant to the reporting person's applicable deferral election in accordance with GE HealthCare's Non-Employee Director Compensation and Benefits Plan.
• F2: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock.
• F3: The price reported represents the weighted average price of shares purchased. These shares were purchased in multiple transactions at prices ranging from $62.97 to $63.01, inclusive. The Reporting Person undertakes to provide to GE HealthCare, any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.